Welcome to our dedicated page for Immutep SEC filings (Ticker: IMMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immutep Limited (IMMP) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Immutep submits current reports on Form 6-K under the Securities Exchange Act of 1934, furnishing investors with official information on clinical progress, regulatory interactions, collaborations and financial updates.
Recent Form 6-K filings include press releases on key milestones such as the global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line non-small cell lung cancer, translational and pathologic response data from the EFTISARC-NEO Phase II trial in soft tissue sarcoma, new data from the AIPAC-003 Phase II breast cancer study, and progress in the IMP761 Phase I program for autoimmune diseases. Other filings report on the successful completion of FDA Project Optimus requirements and agreement on the optimal biological dose for eftilagimod alfa, as well as R&D tax incentive payments from the French government and quarterly activities reports.
Through this page, users can follow how Immutep communicates material developments in its LAG-3–focused pipeline, including oncology and autoimmune programs, to the US market. Each 6-K typically incorporates an exhibit containing the full text of a company announcement, such as clinical trial updates, strategic collaborations like the exclusive licensing agreement with Dr. Reddy’s Laboratories for efti in selected territories, or summaries of cash position and R&D spending.
Stock Titan enhances these filings with AI-powered tools that help readers quickly understand the significance of each document. Summaries highlight the core message of new 6-Ks, while structured views make it easier to compare successive disclosures about the same trial or program. Investors can use this page to stay aligned with Immutep’s official SEC record, track the evolution of its clinical and corporate strategy and reference historical filings for deeper due diligence on IMMP.
IMMUTEP Ltd director Elisabeth Amanda Boyce reports direct ownership of 423,288 Ordinary Shares and several performance rights over additional shares. These performance rights have a $0.00 exercise price and, if vesting conditions are met, are scheduled to vest in tranches on December 1, 2026, December 1, 2027, and December 1, 2028, with expiration dates extending to November 23, 2028 and December 2, 2030.
Immutep Limited reports that the U.S. FDA has granted Orphan Drug Designation to its immunotherapy candidate eftilagimod alfa (efti) for treating Soft Tissue Sarcoma, a rare cancer with significant unmet need. Orphan status can provide regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval.
The designation is supported by Phase II EFTISARC-NEO trial data in 38 evaluable patients, where efti with radiotherapy and KEYTRUDA achieved a median tumour hyalinization/fibrosis of 51.5%, beating the pre-set 35% target and historical ~15% with radiotherapy alone, with immune activation signals and a favourable safety profile.
IMMUTEP Ltd director and officer Marc Voigt has filed an initial ownership report showing substantial equity exposure to the company. He directly holds 14,791,695 Ordinary Shares, plus 450 additional Ordinary Shares, and 85,250 Ordinary Shares are held indirectly through JP Morgan Nominees Australia Limited.
Voigt also holds three tranches of performance rights over 1,200,000 underlying Ordinary Shares each, with a zero exercise price. According to the footnotes, 1,200,000 performance rights are scheduled to vest on December 1, 2026, and further 1,200,000-share tranches are scheduled to vest on December 1, 2027 and December 1, 2028, in each case subject to key performance indicators. The Ordinary Shares are represented by American Depositary Shares.
IMMUTEP Ltd Chief Operating Officer Deanne Diem Miller reported her initial ownership on a Form 3. She directly holds 2,867,305 Ordinary Shares. In addition, she holds 1,800,000 performance rights, each giving a right to receive Ordinary Shares at an exercise price of $0.0000 per share.
These performance rights are structured in three equal tranches of 600,000 underlying Ordinary Shares each, scheduled to vest on December 1, 2026, December 1, 2027, and December 1, 2028. Vesting of the later tranches depends on Ms. Miller achieving specified key performance indicators at the applicable vesting dates.
IMMUTEP Ltd director Pete A. Meyers filed an initial ownership report showing both ordinary shares and performance rights. He holds 4,052,173 Ordinary Shares directly. In addition, he holds performance rights over blocks of 388,889, 758,631, 650,000, and 650,000 underlying Ordinary Shares at an exercise price of $0.0000 per share.
The footnotes state these performance rights were granted on December 16, 2022 and December 2, 2025. Vesting dates run from October 1, 2026 through December 1, 2029, and each grant is dependent on Mr. Meyers meeting specified vesting conditions, with expiration dates extending to December 2, 2030.
IMMUTEP Ltd Chief Medical Officer Stephan Karel Gerard Winckels filed an initial ownership report showing his equity position. He directly holds 92,935 Ordinary Shares and three blocks of 221,708 performance rights each over Ordinary Shares, with vesting dates in 2026, 2027 and 2028 and an exercise price of $0.0000. The vesting of these performance rights depends on achieving specified key performance indicators and they expire in 2030.
IMMUTEP Ltd director Frederic Joseph Daniel Triebel has filed an initial statement of beneficial ownership. The filing shows direct holdings of Ordinary Shares, including 11,353,764 shares in one entry and 170,610 shares in another, which are represented by American Depositary Shares.
The filing also lists performance rights over Ordinary Shares with a zero exercise price. Footnotes state that blocks of 900,000 performance rights are scheduled to vest on December 1 of 2026, 2027 and 2028, with additional performance rights vesting only if Dr. Triebel meets specified key performance indicators at each applicable vesting date.
IMMUTEP Ltd director Dr. Russell Howard has filed an initial Form 3 showing his equity interests in the company. The filing reports performance rights over 50,000 Ordinary Shares granted on November 23, 2023, which may vest on December 1, 2026 if vesting conditions are met. Additional performance rights granted on December 2, 2025 cover 400,154 Ordinary Shares scheduled to vest on December 1, 2026, and two further tranches of 461,746 performance rights each that may vest on December 1, 2027 and December 1, 2028, all subject to specified vesting conditions. The Form 3 also reports 1,717,977 Ordinary Shares held indirectly through Regulus Star Pty Ltd.
IMMUTEP Ltd Chief Development Officer Christian Mueller filed an initial ownership report showing he directly holds 3,774,048 Ordinary Shares. This Form 3 establishes his baseline equity position as a company officer.
Mueller also holds three tranches of performance rights over 1,400,000 Ordinary Shares in total, each with a zero exercise price. Footnotes state 466,667 performance rights are scheduled to vest on December 1, 2026 and another 466,667 on December 1, 2027, while 466,666 are scheduled to vest on December 1, 2028. Vesting of the latter two tranches depends on him achieving specified key performance indicators at each applicable vesting date.
Immutep Limited provided an update on its first-in-human Phase I trial of IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The single ascending dose stage in healthy participants has been completed with dosing up to 14 mg/kg, and IMP761 was well tolerated with no dose-limiting toxicities reported.
The trial has now moved into the multiple ascending dose stage to further assess pharmacokinetics and safety, with completion expected in the third quarter of 2026. Early data show a clear immunosuppressive effect in a controlled antigen challenge model, supporting the planned dose levels for a future Phase II trial in patients with autoimmune conditions.
Immutep plans to present Phase I results for IMP761 at the EULAR congress in London on 4 June 2026 at 1:30 pm UK time. IMP761 targets dysregulated self-antigen-specific memory T cells via LAG-3 agonism, aiming to restore immune balance in major autoimmune diseases such as rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.